Taiwan
· Delayed Price · Currency is TWD BioLASCO Taiwan Statistics
Total Valuation
BioLASCO Taiwan has a market cap or net worth of TWD 868.25 million. The enterprise value is 824.07 million.
| Market Cap | 868.25M |
| Enterprise Value | 824.07M |
Important Dates
The last earnings date was Wednesday, May 14, 2025.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | Jul 26, 2024 |
Share Statistics
BioLASCO Taiwan has 25.61 million shares outstanding. The number of shares has decreased by -0.03% in one year.
| Current Share Class | 25.61M |
| Shares Outstanding | 25.61M |
| Shares Change (YoY) | -0.03% |
| Shares Change (QoQ) | -0.28% |
| Owned by Insiders (%) | 19.76% |
| Owned by Institutions (%) | n/a |
| Float | 18.98M |
Valuation Ratios
The trailing PE ratio is 19.37.
| PE Ratio | 19.37 |
| Forward PE | n/a |
| PS Ratio | 2.85 |
| PB Ratio | 2.07 |
| P/TBV Ratio | 2.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 14.96 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.74, with an EV/FCF ratio of -2,185.87.
| EV / Earnings | 18.35 |
| EV / Sales | 2.70 |
| EV / EBITDA | 11.74 |
| EV / EBIT | 13.92 |
| EV / FCF | -2,185.87 |
Financial Position
The company has a current ratio of 2.62, with a Debt / Equity ratio of 0.26.
| Current Ratio | 2.62 |
| Quick Ratio | 2.26 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | 1.59 |
| Debt / FCF | -285.59 |
| Interest Coverage | 28.73 |
Financial Efficiency
Return on equity (ROE) is 10.22% and return on invested capital (ROIC) is 6.77%.
| Return on Equity (ROE) | 10.22% |
| Return on Assets (ROA) | 6.09% |
| Return on Invested Capital (ROIC) | 6.77% |
| Return on Capital Employed (ROCE) | 11.00% |
| Revenue Per Employee | 3.35M |
| Profits Per Employee | 493,560 |
| Employee Count | 91 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 4.81 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -6.09% in the last 52 weeks. The beta is 0.11, so BioLASCO Taiwan's price volatility has been lower than the market average.
| Beta (5Y) | 0.11 |
| 52-Week Price Change | -6.09% |
| 50-Day Moving Average | 33.40 |
| 200-Day Moving Average | 34.70 |
| Relative Strength Index (RSI) | 53.68 |
| Average Volume (20 Days) | 5,020 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioLASCO Taiwan had revenue of TWD 304.65 million and earned 44.91 million in profits. Earnings per share was 1.75.
| Revenue | 304.65M |
| Gross Profit | 116.34M |
| Operating Income | 56.59M |
| Pretax Income | 56.10M |
| Net Income | 44.91M |
| EBITDA | 65.49M |
| EBIT | 56.59M |
| Earnings Per Share (EPS) | 1.75 |
Balance Sheet
The company has 151.84 million in cash and 107.67 million in debt, giving a net cash position of 44.17 million or 1.72 per share.
| Cash & Cash Equivalents | 151.84M |
| Total Debt | 107.67M |
| Net Cash | 44.17M |
| Net Cash Per Share | 1.72 |
| Equity (Book Value) | 420.31M |
| Book Value Per Share | 16.41 |
| Working Capital | 141.99M |
Cash Flow
In the last 12 months, operating cash flow was 58.05 million and capital expenditures -58.43 million, giving a free cash flow of -377,000.
| Operating Cash Flow | 58.05M |
| Capital Expenditures | -58.43M |
| Free Cash Flow | -377,000 |
| FCF Per Share | -0.01 |
Margins
Gross margin is 38.19%, with operating and profit margins of 18.58% and 14.74%.
| Gross Margin | 38.19% |
| Operating Margin | 18.58% |
| Pretax Margin | 18.41% |
| Profit Margin | 14.74% |
| EBITDA Margin | 21.50% |
| EBIT Margin | 18.58% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 1.65, which amounts to a dividend yield of 4.87%.
| Dividend Per Share | 1.65 |
| Dividend Yield | 4.87% |
| Dividend Growth (YoY) | 10.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 94.09% |
| Buyback Yield | 0.03% |
| Shareholder Yield | 4.91% |
| Earnings Yield | 5.17% |
| FCF Yield | -0.04% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 30, 2018. It was a forward split with a ratio of 1.055.
| Last Split Date | Jul 30, 2018 |
| Split Type | Forward |
| Split Ratio | 1.055 |
Scores
BioLASCO Taiwan has an Altman Z-Score of 4.37.
| Altman Z-Score | 4.37 |
| Piotroski F-Score | n/a |